Obinutuzumab in Primary FSGS

Clinical trial NCT04983888 · COMPLETED

Trial details

NCT number: NCT04983888
Sponsor: Mayo Clinic
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Focal Segmental Glomerulosclerosis

Start date: 2021-11-17
Primary completion: 2025-06-16
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.